Inventiva strengthens leadership team with three C-suite appointments ahead of critical Phase 3 data readout
Summary
Inventiva announced the appointment of a new CFO, CLO, and CPO, strategically strengthening its leadership team in anticipation of the critical Phase 3 data readout for lanifibranor in Q4 2026.
Key Events
-
New Chief Financial Officer Appointed
Axel-Sven Malkomes joins as CFO, bringing over 30 years of investment banking and corporate leadership experience in life sciences, including roles at CureVac and Cardior.
-
New Chief Legal Officer Appointed
Susan Coles is appointed CLO, with over 25 years of experience guiding life science companies through growth and transformation, including previous stints at Inventiva and Vivet Therapeutics.
-
New Chief People Officer Appointed
Pamela Herbster joins as CPO, bringing over 25 years of biopharmaceutical experience in human resource strategies and organizational performance from companies like Sage Therapeutics and EMD Serono.
-
Strategic Timing Ahead of Phase 3 Data
These recruitments are made as Inventiva prepares for the top-line data readout from its NATiV3 Phase 3 trial for lanifibranor, expected in the fourth quarter of 2026, positioning the company for potential commercialization.
Analysis
Inventiva has strategically bolstered its executive team by appointing a new Chief Financial Officer, Chief Legal Officer, and Chief People Officer. These key hires bring extensive experience in finance, legal, and human resources within the life sciences sector. The timing of these appointments is particularly significant as the company prepares for the top-line data readout from its NATiV3 Phase 3 trial for lanifibranor in Q4 2026, a pivotal moment for its lead drug candidate for MASH. This move signals Inventiva's proactive preparation for potential regulatory submissions and commercialization, aiming to ensure robust leadership for its next phase of growth. The smooth transition of the previous CFO and Head of HR into new roles within the company further indicates a well-managed organizational build-out.
At the time of this filing, IVA was trading at $5.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.85 to $7.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.